Impact of early initiation versus national standard of care of antiretroviral therapy in Swaziland's public sector health system: study protocol for a stepped-wedge randomized trial

Fiona J Walsh, Till Bärnighausen, Wim Delva, Yvette Fleming, Gavin Khumalo, Charlotte L Lejeune, Sikhathele Mazibuko, Charmaine Khudzie Mlambo, Ria Reis, Donna Spiegelman, Mandisa Zwane, Velephi Okello, Fiona J Walsh, Till Bärnighausen, Wim Delva, Yvette Fleming, Gavin Khumalo, Charlotte L Lejeune, Sikhathele Mazibuko, Charmaine Khudzie Mlambo, Ria Reis, Donna Spiegelman, Mandisa Zwane, Velephi Okello

Abstract

Background: There is robust clinical evidence to support offering early access to antiretroviral treatment (ART) to all HIV-positive individuals, irrespective of disease stage, to both improve patient health outcomes and reduce HIV incidence. However, as the global treatment guidelines shift to meet this evidence, it is still largely unknown if early access to ART for all (also referred to as "treatment as prevention" or "universal test and treat") is a feasible intervention in the resource-limited countries where this approach could have the biggest impact on the course of the HIV epidemics. The MaxART Early Access to ART for All (EAAA) implementation study was designed to determine the feasibility, acceptability, clinical outcomes, affordability, and scalability of offering early antiretroviral treatment to all HIV-positive individuals in Swaziland's public sector health system.

Methods: This is a three-year stepped-wedge randomized design with open enrollment for all adults aged 18 years and older across 14 government-managed health facilities in Swaziland's Hhohho Region. Primary endpoints are retention and viral suppression. Secondary endpoints include ART initiation, adherence, drug resistance, tuberculosis, HIV disease progression, patient satisfaction, and cost per patient per year. Sites are grouped to transition two at a time from the control (standard of care) to intervention (EAAA) stage at each four-month step. This design will result in approximately one half of the total observation time to accrue in the intervention arm and the other half in the control arm. Our estimated enrolment number, which is supported by conservative power calculations, is 4501 patients over the course of the 36-month study period. A multidisciplinary, mixed-methods approach will be adopted to supplement the randomized controlled trial and meet the study aims. Additional study components include implementation science, social science, economic evaluation, and predictive HIV incidence modeling.

Discussion: A stepped-wedge randomized design is a causally strong and robust approach to determine if providing antiretroviral treatment for all HIV-positive individuals is a feasible intervention in a resource-limited, public sector health system. We expect our study results to contribute to health policy decisions related to the HIV response in Swaziland and other countries in sub-Saharan Africa.

Trial registration: ClinicalTrials.gov, NCT02909218 . Registered on 10 July 2016.

Keywords: Antiretroviral treatment; HIV/AIDS; Prevention; Swaziland.

Conflict of interest statement

Ethics approval and consent to participate

The trial was approved by the Swaziland National Health Research Review Board in July 2014 (Reference Number: MH/599C/FWA 000 15267). All participants must be able and willing to give verbal consent for trial participation. The final report will follow the CONSORT reporting guidelines for cluster trials [26] and the recommendations for reporting stepped-wedge trials proposed by Hemming et al. [27].

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Map of study sites in Hhohho Region
Fig. 2
Fig. 2
Stepped-wedge study design
Fig. 3
Fig. 3
Trial flow diagram

References

    1. UNAIDS . Report on the Global HIV/AIDS Epidemic. Geneva: UNAIDS; 2000.
    1. UNAIDS . Global AIDS Update. Geneva: UNAIDS; 2016.
    1. UNAIDS. Fast-track update on investments needed in the AIDS response (2016). Geneva: UNAIDS. . Accessed 1 Apr 2016.
    1. Government of South Africa. Minister Aaron Motsoaledi: Health Department Budget Vote 2016/2017. 2016. . Accessed 17 July 2016.
    1. Atun R, Chang AY, Ogbuoji O, Silva S, Resch S, Hontelez J, et al. Long-term financing needs for HIV control in sub-Saharan Africa in 2015-2050: a modelling study. BMJ Open. 2016;6:e009656. doi: 10.1136/bmjopen-2015-009656.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505. doi: 10.1056/NEJMoa1105243.
    1. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807. doi: 10.1056/NEJMoa1506816.
    1. World Health Organization . Consolidated guidelines on the use of antiretroviral therapy for treating and preventing HIV infection: guidelines for a public health approach. Geneva: WHO; 2015.
    1. Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomized controlled trial. Trials. 2013;14:1–15. doi: 10.1186/1745-6215-14-230.
    1. Iwuji C, Orne-Gliemann J, Balestre E, Larmarange J, Thiebaut R, Tanser F, et al. Abstract: The impact of universal test and treat on HIV incidence in a rural South African population: ANRS 12249 TasP trial, 2012-2016. In: International AIDS Conference 2016, Durban, South Africa. Durban; 2016. .
    1. World Health Organization . Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach. 2. Geneva: WHO; 2016.
    1. Kingdom of Swaziland. Ministry of Health. National comprehensive HIV package of care for adults and adolescents in Swaziland. 2010. . Accessed 17 July 2016.
    1. Bicego GT, Nkambule R, Peterson I, Reed J, Donnell D, Ginindza H, et al. Recent patterns in population-based HIV prevalence in Swaziland. PLoS One. 2013;8:e77101. doi: 10.1371/journal.pone.0077101.
    1. Kingdom of Swaziland. Ministry of Health. Annual HIV Programs Report 2015.
    1. Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials. 2007;28:182–91. doi: 10.1016/j.cct.2006.05.007.
    1. Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, et al. HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial. Trials. 2014;15:57. doi: 10.1186/1745-6215-15-57.
    1. BCCP: Botswana Combination Prevention Project. . 2015. . Accessed 1 Sept 2016.
    1. SEARCH: Sustainable East Africa Research in Community Health. . 2015. . Accessed 1 Sept 2016.
    1. Orne-Gliemann J, Larmarange J, Boyer S, Iwuji C, McGrath N, Bärnighausen T, et al. Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal. BMC Public Health. 2015;15:209. doi: 10.1186/s12889-015-1344-y.
    1. Liesenborgs J, Meng F, Hens N DW. Simpact Cyan 0.19. . Accessed 5 Aug 2016.
    1. Delva W, Leventhal GE, Helleringer S. Connecting the dots: network data and models in HIV epidemiology. AIDS. 2016;30:2009–20. doi: 10.1097/QAD.0000000000001184.
    1. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561–70. doi: 10.1097/00001648-200009000-00012.
    1. Rotnitzky A, Robins JM. Semiparametric regression estimation in the presence of dependent censoring. Biometrika. 1995;82:805–20. doi: 10.1093/biomet/82.4.805.
    1. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. XX: Wiley, New Jersey. 2004.
    1. Little RJ, D’Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367:1355–60. doi: 10.1056/NEJMsr1203730.
    1. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345(1):e5661. doi: 10.1136/bmj.e5661.
    1. Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ. 2015;350:h391. doi: 10.1136/bmj.h391.

Source: PubMed

3
Sottoscrivi